{
    "id": 3625,
    "fullName": "FGFR2 N549H",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 N549H lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549H confers a gain of function to the Fgfr2 protein as indicated by disengagement of autoinhibitory mechanisms thereby resulting in constitutive activation and downstream pathway activation (PMID: 17525745, PMID: 17803937) and results in elevated kinase activity compared to wild-type Fgfr2 protein in substrate phosphorylation assays (PMID: 28166054).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 702,
                    "pubMedId": 17525745,
                    "title": "Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17525745"
                },
                {
                    "id": 1905,
                    "pubMedId": 17803937,
                    "title": "A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17803937"
                },
                {
                    "id": 14787,
                    "pubMedId": 28166054,
                    "title": "Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28166054"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "N549H",
    "createDate": "03/10/2015",
    "updateDate": "05/23/2019",
    "referenceTranscriptCoordinates": {
        "id": 90258,
        "transcript": "NM_000141",
        "gDna": "chr10:g.121498522T>G",
        "cDna": "c.1645A>C",
        "protein": "p.N549H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10147,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on Infigratinib (BGJ398) treatment (PMID: 28034880).",
            "molecularProfile": {
                "id": 27311,
                "profileName": "FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8146,
                    "pubMedId": 28034880,
                    "title": "Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28034880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10148,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, FGFR2 mutations E565A, K641R, L617V, N549H and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-OPTN fusion after the patient progressed while on Infigratinib (BGJ398) treatment (PMID: 28034880).",
            "molecularProfile": {
                "id": 27312,
                "profileName": "FGFR2 - OPTN FGFR2 N549H FGFR2 V564F FGFR2 E565A FGFR2 L617V FGFR2 K641R"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8146,
                    "pubMedId": 28034880,
                    "title": "Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28034880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3426,
            "profileName": "FGFR2 N549H",
            "profileTreatmentApproaches": [
                {
                    "id": 8957,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 N549H"
                },
                {
                    "id": 8958,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 N549H"
                }
            ]
        },
        {
            "id": 27311,
            "profileName": "FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27312,
            "profileName": "FGFR2 - OPTN FGFR2 N549H FGFR2 V564F FGFR2 E565A FGFR2 L617V FGFR2 K641R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 90258,
            "transcript": "NM_000141",
            "gDna": "chr10:g.121498522T>G",
            "cDna": "c.1645A>C",
            "protein": "p.N549H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90260,
            "transcript": "NM_023029",
            "gDna": "chr10:g.121488065T>G",
            "cDna": "c.1645A>C",
            "protein": "p.N549H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90259,
            "transcript": "NM_001144915",
            "gDna": "chr10:g.121488065T>G",
            "cDna": "c.1645A>C",
            "protein": "p.N549H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90261,
            "transcript": "NM_001144919",
            "gDna": "chr10:g.121488068T>G",
            "cDna": "c.1645A>C",
            "protein": "p.N549H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}